Creo Medical Group (CREO) Share Price, News & Analysis

Company Overview

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures. For more information, please refer to the website www.creomedical.com

Key Stats

• Today's Range: 12 to 12.50
• 50-Day Range: 12 to 19.75
• 52-Week Range: 11.75 to 41
• Volume: 1.77 million shs
• Average Volume: 809,611 shs
• Market Capitalization: £48.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CREO Stock Analysis - Frequently Asked Questions

How have CREO shares performed this year?

Creo Medical Group's stock was trading at GBX 20.40 on January 1st, 2025. Since then, CREO stock has decreased by 41.2% and is now trading at GBX 12.
View the best growth stocks for 2025 here.

How were Creo Medical Group's earnings last quarter?

Creo Medical Group PLC (LON:CREO) issued its quarterly earnings results on Tuesday, October, 1st. The company reported ($0.03) earnings per share (EPS) for the quarter. Creo Medical Group had a negative net margin of 73.93% and a negative trailing twelve-month return on equity of 41.79%.

How do I buy shares of Creo Medical Group?

Shares of CREO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Creo Medical Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Creo Medical Group investors own include Aviva (AV), IQE (IQE), Lloyds Banking Group (LLOY), Barclays (BARC), BP (BP), BT Group (BT.A) and Coats Group (COA).

Company Calendar

• Last Earnings: 10/01/2024
• Today: 4/05/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:CREO
• CIK: N/A
• Web: creomedical.com
• Phone: +44-1291-606005
• Fax: N/A
• Employees: 279
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (6.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-25,038,241.40
• Net Margins: -73.93%
• Pretax Margin: N/A
• Return on Equity: -41.79%
• Return on Assets: -20.09%

Debt

• Debt-to-Equity Ratio: 29.96
• Current Ratio: 3.24
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: £33.87 million
• Price / Sales: 1.43
• Cash Flow: GBX 4.94 per share
• Price / Cash Flow: 2.43
• Book Value: GBX 13.11 per share
• Price / Book: 0.92

Miscellaneous

• Outstanding Shares: 404,265,846
• Free Float: N/A
• Market Cap: £48.51 million
• Optionable: Not Optionable
• Beta: 0.86